Doc Morris Reports Significant Growth in Prescription Drug Sales

Doc Morris has announced a remarkable increase of 52.3% in revenue from prescription medications in the first quarter of this year compared to the previous year. This surge is attributed to a loyal customer base, effective marketing strategies, and the introduction of new telemedicine services.

The company's overall revenue also reflects positive growth. In comparison to the previous year, external sales rose by 13% to reach 296.5 million Swiss francs. Specifically, sales in Germany increased by 13.8%, amounting to 280.1 million Swiss francs. In the broader European market, Doc Morris experienced a revenue rise of 7.6%, equating to 16.4 million Swiss francs. Additionally, the number of active customers grew from 10.3 million at the end of December 2024 to 10.5 million by the end of March 2025.

Looking ahead, Doc Morris aims to achieve at least a 40% growth in prescription sales for the year 2025. In the over-the-counter (OTC) segment, the company is targeting growth in the high single-digit percentage range. The company remains optimistic about its telemedicine provider, Teleclinic, which reported an impressive revenue growth of over 100% year-on-year in the first quarter of 2025. Doc Morris anticipates that Teleclinic's revenue will more than double this year, with a mid-term outlook projecting solid increases in the high double-digit percentage range.

This growth trajectory highlights the effectiveness of Doc Morris's strategic initiatives, including enhanced customer engagement and innovative service offerings. The company continues to adapt to changing market dynamics and consumer preferences, positioning itself as a key player in the pharmaceutical distribution landscape.